HER2-targeted antibody drug conjugates for ovarian cancer therapy-Reference-Cited by-同舟云学术

HER2-targeted antibody drug conjugates for ovarian cancer therapy

Published:2016-10 Issue: Volume:93 Page:274-286
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Jiang Jing,Dong Lihou,Wang Lei,Wang Ling,Zhang Jing,Chen Fang,Zhang Xiuli,Huang Min,Li Shenjun,Ma Weiwei,Xu Qiaoyu,Huang Changjiang,Fang Jianmin,Wang Chunhua

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference43 articles.

1. HER2-directed therapy: current treatment options for HER2-positive breast cancer;Ahmed;Breast Cancer,2015

2. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer;Amiri-Kordestani;Clin. Cancer Res.,2014

3. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation;Anido;EMBO J.,2006

4. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer;Barginear;Mol. Med.,2012

5. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer;Beeram;Cancer,2012

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study;Cancer Communications;2024-06-28

2. Elderly patients with advanced HER2-positive breast cancer with liver metastases benefit from low dose disitamab vedotin (RC48): case series and literature review;Anti-Cancer Drugs;2024-05-03

3. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions;Biomedicine & Pharmacotherapy;2024-05

4. Development and validation of bioanalytical methods to support clinical study of disitamab vedotin;Bioanalysis;2024-03-26

5. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer;Journal of Experimental & Clinical Cancer Research;2024-02-26